{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:03:06Z","timestamp":1794585786697,"version":"4.9.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127356","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T15:13:34Z","timestamp":1749222814000},"page":"127356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["A review of currently licensed mucosal COVID-19 vaccines"],"prefix":"10.1016","volume":"61","author":[{"given":"Alina","family":"Tscherne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127356_bb0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines - immunity, variants","volume":"387","author":"Barouch","year":"2022","journal-title":"Boosters N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000468","article-title":"T cell immune memory after covid-19 and vaccination","volume":"2","author":"Wang","year":"2023","journal-title":"BMJ Med"},{"issue":"2434\u201351","key":"10.1016\/j.vaccine.2025.127356_bb0050","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127356_bb0055","doi-asserted-by":"crossref","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127356_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/14760584.2023.2174529","article-title":"Understanding the mechanisms for COVID-19 vaccine\u2019s protection against infection and severe disease","volume":"22","author":"Yang","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0065","first-page":"14","article-title":"SARS-CoV-2: evolution and emergence of new viral variants","author":"Flores-Vega","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127356_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12250-021-00376-w","article-title":"Protective efficacy of inactivated vaccine against SARS-CoV-2 infection in mice and non-human Primates","volume":"36","author":"Yao","year":"2021","journal-title":"Virol Sin"},{"key":"10.1016\/j.vaccine.2025.127356_bb0075","first-page":"218","article-title":"Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP","author":"Solforosi","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijmr.IJMR_4431_20","article-title":"Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates","volume":"153","author":"Mukhopadhyay","year":"2021","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2025.127356_bb0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127356_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104585","article-title":"Mucosal vaccines for SARS-CoV-2: triumph of hope over experience","volume":"92","author":"Pilapitiya","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127356_bb0095","doi-asserted-by":"crossref","first-page":"1433452","DOI":"10.3389\/fimmu.2024.1433452","article-title":"Mucosal immunity in COVID-19: a comprehensive review","volume":"15","author":"Alqahtani","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110026","article-title":"Mucosal vaccines for viral diseases: status and prospects","volume":"593","author":"Ma","year":"2024","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127356_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109210","article-title":"SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract","volume":"27","author":"Escalera","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2025.127356_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104893","article-title":"SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses","volume":"98","author":"Puhach","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127356_bb0115","first-page":"13","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02280-23","article-title":"Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection","author":"Bhavsar","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127356_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/14760584.2024.2326094","article-title":"Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines","volume":"23","author":"Zhang","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0010","unstructured":"CanSinoBIO CanSinoBIO\u2019s convidecia air\u2122 approved for emergency use in Morocco.Accessed February 22, 2025. http:\/\/47.99.161.107\/detail-3927."},{"key":"10.1016\/j.vaccine.2025.127356_bb0020","unstructured":"CanSinoBIO CanSinoBIO\u2019s convidecia air\u00ae receives approval in Indonesia. Accessed February 22, 2025. http:\/\/47.99.161.107\/detail-3941."},{"key":"10.1016\/j.vaccine.2025.127356_bb0025","series-title":"Bharat Biotech\u2019s iNCOVACC world\u2019s first intra nasal vaccine receives approval for emergency use in India","author":"Biotech","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127356_bb0030","unstructured":"Times T. Two homegrown vaccines receive emergency use license. Accessed February 22, 2025. https:\/\/www.tehrantimes.com\/news\/466570\/Two-homegrown-vaccines-receive-emergency-use-license."},{"key":"10.1016\/j.vaccine.2025.127356_bb0035","unstructured":"PLOS Progress on intranasal & oral Covid vaccines \u2013 Plus a US government funding boost. Accessed February 22, 2025. https:\/\/absolutelymaybe.plos.org\/2023\/04\/21\/progress-on-intranasal-oral-covid-vaccines-plus-a-us-government-funding-boost\/."},{"key":"10.1016\/j.vaccine.2025.127356_bb0125","unstructured":"Icosagen. BioBlock\u00ae A Novel prophylactic nasal spray with antibodies against SARS-CoV-2 developed by icosagen, has received marketing authorization and Is available for sale in estonia. Accessed February 27, 2025. https:\/\/www.icosagen.com\/news\/our-nasal-spray-with-antibodies-against-sars-cov-2-is-finally-on-estonian-market\/."},{"key":"10.1016\/j.vaccine.2025.127356_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-024-02043-4","article-title":"Mucosal immune response in biology, disease prevention and treatment","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127356_bb0135","first-page":"12","article-title":"Vaccine strategies to elicit mucosal immunity","author":"Song","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7774\/cevr.2022.11.3.235","article-title":"Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants","volume":"11","author":"Anggraeni","year":"2022","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2025.127356_bb0145","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","article-title":"Advances in intranasal vaccine delivery: a promising non-invasive route of immunization","volume":"41","author":"Kehagia","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127356_bb0150","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14760584.2021.1903878","article-title":"Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19","volume":"21","author":"Heida","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/etm.2024.12511","article-title":"Recent development of oral vaccines (review)","volume":"27","author":"Liu","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0160","first-page":"11","article-title":"Next generation mucosal vaccine strategy for respiratory pathogens","author":"Dotiwala","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-022-00485-x","article-title":"Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies","volume":"7","author":"Hameed","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0175","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127356_bb0235","doi-asserted-by":"crossref","first-page":"1063679","DOI":"10.3389\/fimmu.2022.1063679","article-title":"Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)","volume":"13","author":"Sunagar","year":"2022","journal-title":"Front Immunol"},{"issue":"169\u201384","key":"10.1016\/j.vaccine.2025.127356_bb0240","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127356_bb0250","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/22221751.2022.2119169","article-title":"Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine sputnik V in mice and non-human primates","volume":"11","author":"Tukhvatulin","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127356_bb0270","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","article-title":"A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2","volume":"67","author":"Chen","year":"2022","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103762","article-title":"Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models","volume":"75","author":"Zhou","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127356_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836745","article-title":"Safety and efficacy of combined intramuscular\/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models","volume":"13","author":"Banihashemi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268806","article-title":"Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents","volume":"17","author":"Kangro","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127356_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110326","article-title":"Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets","volume":"27","author":"Gildemann","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2025.127356_bb0180","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127356_bb0185","article-title":"Vaccination with adenovirus type 5 vector-based COVID-19 vaccine as the primary series in adults: a randomized, double-blind, placebo-controlled phase 1\/2 clinical trial","volume":"12","author":"Zhu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0190","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-Centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0195","doi-asserted-by":"crossref","first-page":"1461419","DOI":"10.3389\/fimmu.2024.1461419","article-title":"Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0200","doi-asserted-by":"crossref","first-page":"1239179","DOI":"10.3389\/fimmu.2023.1239179","article-title":"Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0210","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2213-2600(23)00129-7","volume":"11","author":"Huang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41541-024-01003-x","article-title":"Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial","volume":"9","author":"Chew","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0225","volume":"13","author":"Xu","year":"2024","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127356_bb0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/jiad134","article-title":"Environmental impact assessment for the use of an orally aerosolized adenovirus Type-5 vector-based COVID-19 vaccine in randomized clinical trials","volume":"228","author":"Xia","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127356_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin((R)))","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127356_bb0280","first-page":"11","article-title":"A phase 1, randomized, double-blinded, placebo-controlled and dose-escalation study to evaluate the safety and immunogenicity of the intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in healthy adults","author":"Zhang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0285","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","article-title":"Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Zhu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0290","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0300","article-title":"Immunogenicity and safety of a combined intramuscular\/intranasal recombinant spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old: a randomized, double-blind, placebo-controlled, phase I trial","volume":"11","author":"Dodaran","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127356_bb0305","first-page":"3012","article-title":"Phase II, safety and immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 vaccine in adults aged 18-70 years; a randomized","volume":"112","author":"Mohazzab","year":"2023","journal-title":"Double-Blind Clinical Trial J Pharm Sci"},{"key":"10.1016\/j.vaccine.2025.127356_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27370","article-title":"Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: a phase III, non-inferiority trial","volume":"10","author":"Solaymani-Dodaran","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.vaccine.2025.127356_bb0315","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-024-03295-1","article-title":"Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial","volume":"22","author":"Erfanpoor","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0320","first-page":"12","article-title":"Safety and immunogenicity of intranasal Razi Cov Pars as a COVID-19 booster vaccine in adults: promising results from a groundbreaking clinical trial","author":"Fallah Mehrabadi","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"722\u201333","key":"10.1016\/j.vaccine.2025.127356_bb0205","article-title":"A universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127356_bb0255","first-page":"10","article-title":"Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines","author":"Wang","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127356_bb0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.1998.9508","article-title":"Influenza a virus lacking the NS1 gene replicates in interferon-deficient systems","volume":"252","author":"Garc\u00eda-Sastre","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127356_bb0265","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/JVI.01920-08","article-title":"Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza","volume":"83","author":"Steel","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127356_bb0325","unstructured":"Medihex BioBlock\u00ae-Nasal spray with antibodies against SARS-CoV-2, which helps to prevent the spread of the virus. Accessed February 26, 2025. https:\/\/www.medihex.com\/en\/products\/bioblock\/."},{"key":"10.1016\/j.vaccine.2025.127356_bb0340","unstructured":"Chemi-Pharm\u00ae The bioblock\u00ae nasal spray clinical study. Accessed February 27, 2025. https:\/\/www.chemi-pharm.com\/the-bioblock-nasal-spray-clinical-study\/."},{"key":"10.1016\/j.vaccine.2025.127356_bb0345","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.biologicals.2020.08.006","article-title":"SARS-CoV-2 controlled human infection models: ethics, challenge agent production and regulatory issues","volume":"67","author":"Baay","year":"2020","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.127356_bb0350","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127356_bb0355","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127356_bb0360","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2666-5247(24)00025-9","article-title":"Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-Centre, open-label, phase 1 controlled human infection study","volume":"5","author":"Jackson","year":"2024","journal-title":"Lancet Microbe"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500653X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500653X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T21:24:24Z","timestamp":1755897864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500653X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"alternative-id":["S0264410X2500653X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127356","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of currently licensed mucosal COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127356"}}